•
Taiwan-based PharmaEssentia Corporation (TPE: 6446) has announced the successful closing of a secondary offering of Global Depositary Receipt (GDR) shares. A total of 34 million shares of common stock were offered at a price of USD 13.61 per share, resulting in a capital raise of USD 462.7 million. The shares…
•
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its 2022 financial report, recording HKD 1.233 billion (USD 157 million) in revenues, marking a 2.6% year-on-year (YOY) decrease. In-licensed products contributed HKD 733 million (USD 93.73 million), accounting for 59.5% of total revenues, while patented drugs and generics made up…
•
Reistone Biopharma Co., Ltd, a company incubated by Hengrui Pharmaceuticals (SHA: 600276) with an investment of USD 100 million in 2018, has obtained clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 drug, RSS0343, intended to treat non-cystic fibrosis bronchiectasis (NCFB). Understanding Non-Cystic Fibrosis Bronchiectasis…
•
German healthcare giant Siemens Healthineers (ETR: SHL) has partnered with the China Chest Pain Center to launch the “Rising Star smart chest pain center standardized construction training program.” This initiative is designed to enhance the standardized construction of chest pain treatment processes and improve clinical intervention diagnosis and treatment capabilities.…
•
Nanjing-based Neurodawn Pharmaceutical Co., Ltd has announced that its Category 1 drug, injectable Y-1, has obtained clinical trial approval from the National Medical Products Administration (NMPA) for the treatment of primary intracranial malignant tumors. TRPML1 Inhibitor’s Non-Clinical Study ResultsNon-clinical studies have demonstrated that the TRPML1 inhibitor, Y-1, can effectively inhibit…
•
Biosion, a global, clinical-stage biotech company dedicated to developing antibody-based therapies for immune and oncologic diseases, has successfully raised tens of millions of renminbi in a Series B+ financing round. The funds will be allocated to the development and advancement of the company’s innovative pipelines and to support its robust…
•
Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a China-based pharmaceutical company, has released its 2022 financial report, recording RMB 21.275 billion (USD 3.08 billion) in revenues, marking a 17.87% year-on-year (YOY) decrease. Innovative drugs contributed RMB 8.116 billion (USD 1.77 billion) to the total revenues. The net profit attributable to the owners…
•
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary, Legend Biotech Corporation (NASDAQ: LEGN), has filed a 6-K with the US Securities and Exchange Commission and published clinical studies with the European Hematology Association (EHA) regarding its chimeric antigen receptor (CAR)-T therapies. The release…
•
China-based HealZen Therapeutics has entered into a licensing agreement with compatriot firm NeuShen, focusing on the transfer of rights related to HealZen’s self-developed small-molecule central nervous system (CNS) programs. According to the agreement, NeuShen will secure global exclusive development, regulatory, and commercialization rights to the program, which includes indications for…
•
China-based Hasten Biopharmaceutical Co., Ltd has reportedly received USD 315 million in a fundraising round co-led by CBC Group and the Abu Dhabi sovereign wealth fund Mubadala Investment Company, with participation from other unnamed institutional investors. The capital raised is intended to fund future acquisitions and deal-making focused on innovative…
•
China-based Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204) has announced plans to raise RMB 580 million (USD 84.1 million) through a private placement, with the net proceeds designated for innovative drug research and development (R&D). This move follows previous unsuccessful attempts to raise funds through private placements of RMB 1.08…
•
China-based contract research organization (CRO) Sangon Biotech has secured RMB 2 billion (USD 290.3 million) in its first financing round, led by GL Capital. Joining the round are CITIC Private Equity, Greenwoods Investment, Huagai Capital, and Guokai Technology Venture Investment. This significant funding will enable Sangon to accelerate human resource…
•
Shenzhen 01 Life Science and Technology Ltd. Co., Ltd, a company specializing in human big data-driven microecology high-throughput screening and application transformation, has reportedly raised RMB 100 million (USD 14.5 million) in a Series B1 financing round. The investors in this round include Green Pine Capital Partners, Seas Capital, Green…
•
U.S.-based pharmaceutical giant Pfizer (NYSE: PFE) has reported receiving an additional indication approval from the National Medical Products Administration (NMPA) for its globally successful vaccine, Prevenar 13. The approval extends the vaccine’s use to infants and children aged between 6 weeks to 5 years (before the 6th birthday), expanding the…
•
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235), a China-based biopharmaceutical company, has announced that the global RATIONALE 305 trial has successfully met its primary endpoint of overall survival. The trial demonstrated that tislelizumab, in combination with chemotherapy, showed superior overall survival (OS) compared to chemotherapy alone in patients with advanced…
•
China-based nerve and peripheral vascular interventional device developer Zylox-Tonbridge Medical Technology (HKG: 2190) has announced a strategic partnership with Guangdong Hicicare Science Co., Ltd. The collaboration aims to promote and sell Zylox-Tonbridge’s peripheral vascular intervention and neurovascular intervention guide wire products in China. Financial details of the agreement were not…
•
Shanghai Ark Biopharmaceutical Co., Ltd’s Initial Public Offering (IPO) filing to the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR) has been accepted for review by the exchange, with expectations to raise RMB 1.997 billion (USD 289.6 million). This move follows the company’s previous withdrawal of an IPO filing in Hong…
•
Hunan Warrant Pharmaceutical Co., Ltd (SHA: 688799), a China-based pharmaceutical company, has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its generic version of Menarini’s brivudine. This approval signifies that Warrant Pharma’s version of the drug has successfully passed the generic quality consistency evaluation (GQCE) and…
•
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has published the results of the Phase III Neotorch study for its programmed death-1 (PD-1) inhibitor Tuoyi (toripalimab) combined with chemotherapy for the perioperative treatment of resectable non-small cell lung cancer (NSCLC) at the American Society of Clinical Oncology (ASCO) Plenary Series this…
•
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a China-based pharmaceutical company, has entered into a licensing agreement with South Korean firm Kainos Medicine Inc., concerning Kainos’ ainuovirine (ACC007) and its fixed dose preparation ainuovirine, lamivudine, tenofovir disoproxil (ACC008). The agreement grants Aidea commercial, development, and promotion rights for these drugs…